Michael Ittmann

List of Publications by Year in Descending Order

229 papers	21,167 citations	66 h-index	141 g-index
241 ext. papers	23,997 ext. citations	8.8 avg, IF	6.28 L-index

#	Paper	IF	Citations
229	AZD4547 targets the FGFR/Akt/SOX2 axis to overcome paclitaxel resistance in head and neck cancer. *Cellular Oncology (Dordrecht)*, **2021**, 1	7.2	1
228	CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation. *Neoplasia*, **2021**, 23, 1147-1165	6.4	1
227	INPP4B protects from metabolic syndrome and associated disorders. *Communications Biology*, **2021**, 4, 416	6.7	2
226	CASC11 promotes aggressiveness of prostate cancer cells through miR-145/IGF1R axis. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 891-902	6.2	0
225	Inhibition of CAMKK2 impairs autophagy and castration-resistant prostate cancer via suppression of AMPK-ULK1 signaling. *Oncogene*, **2021**, 40, 1690-1705	9.2	8
224	MEX3D is an oncogenic driver in prostate cancer. *Prostate*, **2021**, 81, 1202-1213	4.2	2
223	RNF144A deficiency promotes PD-L1 protein stabilization and carcinogen-induced bladder tumorigenesis. *Cancer Letters*, **2021**, 520, 344-360	9.9	2
222	Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates. *Advanced Therapeutics*, **2021**, 4, 2000163	4.9	13
221	Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer. *Cancer Discovery*, **2020**, 10, 1374-1387	24.4	22
220	Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases. *Histopathology*, **2020**, 77, 890-899	7.3	3
219	CD8 infiltration is associated with disease control and tobacco exposure in intermediate-risk oropharyngeal cancer. *Scientific Reports*, **2020**, 10, 243	4.9	4
218	Kallikrein gene family as biomarkers for recurrent prostate cancer. *Croatian Medical Journal*, **2020**, 61, 450-456	1.6	1
217	Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. *Prostate*, **2020**, 80, 65-73	4.2	14
216	Short-term RANKL exposure initiates a neoplastic transcriptional program in the basal epithelium of the murine salivary gland. *Cytokine*, **2019**, 123, 154745	4	1
215	Comparative analysis of p16 expression among African American and European American prostate cancer patients. *Prostate*, **2019**, 79, 1274-1283	4.2	4
214	JNK represses Lkb-deficiency-induced lung squamous cell carcinoma progression. *Nature Communications*, **2019**, 10, 2148	17.4	13
213	Methionine-Homocysteine Pathway in African-American Prostate Cancer. *JNCI Cancer Spectrum*, **2019**, 3, pkz019	4.6	6

212	Moving Beyond Gleason Scoring. *Archives of Pathology and Laboratory Medicine*, **2019**, 143, 565-570	5	8
211	Spatially Restricted Stromal Wnt Signaling Restrains Prostate Epithelial Progenitor Growth through Direct and Indirect Mechanisms. *Cell Stem Cell*, **2019**, 24, 753-768.e6	18	29
210	DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism. *Carcinogenesis*, **2019**, 40, 1332-1340	4.6	4
209	Association of Genetic Ancestry With DNA Methylation Changes in Prostate Cancer Disparity. *Anticancer Research*, **2019**, 39, 5861-5866	2.3	3
208	ERR1 and PGC1β associated mitochondrial alterations correlate with pan-cancer disparity in African Americans. *Journal of Clinical Investigation*, **2019**, 129, 2351-2356	15.9	13
207	SAT-326 INPP4B Suppresses Prostate Inflammation And Protects Mice Fed With High-fat Diet From The Development Of Prostate Intraepithelial Neoplasia. *Journal of the Endocrine Society*, **2019**, 3,	0.4	78
206	ING5 inhibits cancer aggressiveness by inhibiting Akt and activating p53 in prostate cancer. *Cell Biology International*, **2019**, 44, 242	4.5	2
205	Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. *Nature Metabolism*, **2019**, 1, 70-85	14.6	58
204	MicroRNAs as prognostic markers in prostate cancer. *Prostate*, **2019**, 79, 265-271	4.2	19
203	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. *Clinical Cancer Research*, **2018**, 24, 2182-2193	12.9	49
202	Anatomy and Histology of the Human and Murine Prostate. *Cold Spring Harbor Perspectives in Medicine*, **2018**, 8,	5.4	20
201	Impact of diet on irinotecan toxicity in mice. *Chemico-Biological Interactions*, **2018**, 291, 87-94	5	8
200	TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis. *Journal of Clinical Investigation*, **2018**, 128, 3129-3143	15.9	34
199	Differential Expression of Tight Junctions and Cell Polarity Genes in Human Colon Cancer. *Exploratory Research and Hypothesis in Medicine*, **2018**, 3, 14-19	1	1
198	Fibroblast growth factor receptor signaling plays a key role in transformation induced by the TMPRSS2/ERG fusion gene and decreased PTEN. *Oncotarget*, **2018**, 9, 14456-14471	3.3	5
197	Gene Expression Analysis. *Molecular Pathology Library*, **2018**, 153-167		
196	Influence of the neural microenvironment on prostate cancer. *Prostate*, **2018**, 78, 128-139	4.2	36
195	Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers. *Nature Communications*, **2018**, 9, 4080	17.4	78

194	Jagged1 upregulation in prostate epithelial cells promotes formation of reactive stroma in the Pten null mouse model for prostate cancer. *Oncogene*, **2017**, 36, 618-627	9.2	23
193	SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein. *Oncogene*, **2017**, 36, 4767-4777	9.2	63
192	RET Signaling in Prostate Cancer. *Clinical Cancer Research*, **2017**, 23, 4885-4896	12.9	29
191	A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis. *Neoplasia*, **2017**, 19, 421-428	6.4	8
190	RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression. *Cancer Research*, **2017**, 77, 4247-4257	10.1	18
189	A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. *Cancer Cell*, **2017**, 31, 820-832.e3	24.3	286
188	Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. *European Urology*, **2017**, 72, 641-649	10.2	111
187	SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. *Cancer Cell*, **2017**, 31, 436-451	24.3	116
186	Cellular interactions of the phosphorylated form of AKT in prostate cancer. *Human Pathology*, **2017**, 63, 98-109	3.7	3
185	Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. *Cancer Cell*, **2017**, 32, 474-489.e6	24.3	280
184	Pan-urologic cancer genomic subtypes that transcend tissue of origin. *Nature Communications*, **2017**, 8, 199	17.4	35
183	Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. *Cell*, **2017**, 171, 950-965.e28	56.2	451
182	Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. *Oncotarget* , **2017**, 8, 6179-6192	3.3	14
181	miR-33a is a tumor suppressor microRNA that is decreased in prostate cancer. *Oncotarget*, **2017**, 8, 60243-60256	3.3	17
180	Expression of pattern recognition receptor genes and mortality in patients with colorectal adenocarcinoma. *International Journal of Molecular Epidemiology and Genetics*, **2017**, 8, 8-18	0.9	5
179	MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer. *Cancer Research*, **2016**, 76, 6290-6298	10.1	35
178	CELF1 is a central node in post-transcriptional regulatory programmes underlying EMT. *Nature Communications*, **2016**, 7, 13362	17.4	41
177	Neuronal Trans-Differentiation in Prostate Cancer Cells. *Prostate*, **2016**, 76, 1312-25	4.2	16

176	Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. *Nature Communications*, **2016**, 7, 11612	17.4	44
175	Dysregulation of miRNAs-COUP-TFII-FOXM1-CENPF axis contributes to the metastasis of prostate cancer. *Nature Communications*, **2016**, 7, 11418	17.4	74
174	Functional annotation of rare gene aberration drivers of pancreatic cancer. *Nature Communications*, **2016**, 7, 10500	17.4	47
173	A Polymorphism in the FGFR4 Gene Is Associated With Risk of Neuroblastoma and Altered Receptor Degradation. *Journal of Pediatric Hematology/Oncology*, **2016**, 38, 131-8	1.2	11
172	Cells Comprising the Prostate Cancer Microenvironment Lack Recurrent Clonal Somatic Genomic Aberrations. *Molecular Cancer Research*, **2016**, 14, 374-84	6.6	25
171	Oxidative stress promotes benign prostatic hyperplasia. *Prostate*, **2016**, 76, 58-67	4.2	52
170	Ampullary Cancers Harbor ELF3 Tumor Suppressor Gene Mutations and Exhibit Frequent WNT Dysregulation. *Cell Reports*, **2016**, 14, 907-919	10.6	75
169	Inhibition of FOXC2 restores epithelial phenotype and drug sensitivity in prostate cancer cells with stem-cell properties. *Oncogene*, **2016**, 35, 5963-5976	9.2	50
168	Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. *Clinical Cancer Research*, **2016**, 22, 3937-49	12.9	20
167	The role of miR-145 in stem cell characteristics of human laryngeal squamous cell carcinoma Hep-2 cells. *Tumor Biology*, **2016**, 37, 4183-92	2.9	26
166	Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. *Journal of Clinical Investigation*, **2016**, 126, 2626-41	15.9	38
165	A Versatile Gene Delivery System for Efficient and Tumor Specific Gene Manipulation. *Discoveries*, **2016**, 4,	3.7	3
164	Neuroblastoma patient outcomes, tumor differentiation, and ERK activation are correlated with expression levels of the ubiquitin ligase UBE4B. *Genes and Cancer*, **2016**, 7, 13-26	2.9	7
163	The essential role of GATA transcription factors in adult murine prostate. *Oncotarget*, **2016**, 7, 47891-47903	5.5	11
162	Positive association of collagen type I with non-muscle invasive bladder cancer progression. *Oncotarget*, **2016**, 7, 82609-82619	3.3	32
161	GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells. *Oncotarget*, **2016**, 7, 45171-45185	3.3	29
160	The tumor suppressive miR-200b subfamily is an ERG target gene in human prostate tumors. *Oncotarget*, **2016**, 7, 37993-38003	3.3	17
159	The Germ Cell Gene TDRD1 as an ERG Target Gene and a Novel Prostate Cancer Biomarker. *Prostate*, **2016**, 76, 1271-84	4.2	12

158	Role of miR-145 in human laryngeal squamous cell carcinoma. *Head and Neck*, **2016**, 38, 260-6	4.2	34
157	The role of ATP-binding cassette transporter genes in the progression of prostate cancer. *Prostate*, **2016**, 76, 434-44	4.2	21
156	Identification of microRNA profile specific to cancer stem-like cells directly isolated from human larynx cancer specimens. *BMC Cancer*, **2016**, 16, 853	4.8	12
155	Non-Cell-Autonomous Regulation of Prostate Epithelial Homeostasis by Androgen Receptor. *Molecular Cell*, **2016**, 63, 976-89	17.6	52
154	Expression of ERG protein in prostate cancer: variability and biological correlates. *Endocrine-Related Cancer*, **2015**, 22, 277-87	5.7	19
153	Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. *Cancer Investigation*, **2015**, 33, 251-8	2.1	63
152	Genome-wide differentially methylated genes in prostate cancer tissues from African-American and Caucasian men. *Epigenetics*, **2015**, 10, 319-28	5.7	40
151	Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes. *Nature Medicine*, **2015**, 21, 524-9	50.5	398
150	The Molecular Taxonomy of Primary Prostate Cancer. *Cell*, **2015**, 163, 1011-25	56.2	1713
149	Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer. *International Journal of Cancer*, **2015**, 136, 875-9	7.5	34
148	Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors. *PLoS ONE*, **2015**, 10, e0128467	3.7	9
147	Function of phosphorylation of NF-kB p65 ser536 in prostate cancer oncogenesis. *Oncotarget*, **2015**, 6, 6281-94	3.3	44
146	Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression. *Hormones and Cancer*, **2015**, 6, 67-86	5	6
145	Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. *Journal of Clinical Investigation*, **2015**, 125, 1174-88	15.9	63
144	FGF23 promotes prostate cancer progression. *Oncotarget*, **2015**, 6, 17291-301	3.3	59
143	The senescence-associated secretory phenotype promotes benign prostatic hyperplasia. *American Journal of Pathology*, **2014**, 184, 721-31	5.8	28
142	HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. *Investigational New Drugs*, **2014**, 32, 235-242	4.3	18
141	Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E592-600	11.5	130

140	T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo. *Clinical Cancer Research*, **2014**, 20, 962-71	12.9	58
139	FGFR1-WNT-TGF- signaling in prostate cancer mouse models recapitulates human reactive stroma. *Cancer Research*, **2014**, 74, 609-20	10.1	29
138	Genes upregulated in prostate cancer reactive stroma promote prostate cancer progression in vivo. *Clinical Cancer Research*, **2014**, 20, 100-9	12.9	26
137	Recruitment of CD34(+) fibroblasts in tumor-associated reactive stroma: the reactive microvasculature hypothesis. *American Journal of Pathology*, **2014**, 184, 1860-70	5.8	33
136	Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells. *PLoS ONE*, **2014**, 9, e106289	3.7	31
135	GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 18261-6	11.5	76
134	Increased Notch signalling inhibits anoikis and stimulates proliferation of prostate luminal epithelial cells. *Nature Communications*, **2014**, 5, 4416	17.4	55
133	Differential expression of stem cell markers and ABCG2 in recurrent prostate cancer. *Prostate*, **2014**, 74, 1498-505	4.2	38
132	miR-1 and miR-133b are differentially expressed in patients with recurrent prostate cancer. *PLoS ONE*, **2014**, 9, e98675	3.7	63
131	Stromal TGF- signaling induces AR activation in prostate cancer. *Oncotarget*, **2014**, 5, 10854-69	3.3	28
130	Identification of novel DNA-methylated genes that correlate with human prostate cancer and high-grade prostatic intraepithelial neoplasia. *Prostate Cancer and Prostatic Diseases*, **2013**, 16, 292-300	6.2	34
129	Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2. *Molecular Oncology*, **2013**, 7, 484-96	7.9	29
128	MicroRNA expression profiling reveals the potential function of microRNA-31 in chordomas. *Journal of Neuro-Oncology*, **2013**, 115, 143-51	4.8	41
127	COUP-TFII inhibits TGF- induced growth barrier to promote prostate tumorigenesis. *Nature*, **2013**, 493, 236-40	50.4	125
126	IRIS iQ200 workstation as a screen for performing urine culture. *Diagnostic Microbiology and Infectious Disease*, **2013**, 75, 5-8	2.9	13
125	Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. *Journal of Molecular Diagnostics*, **2013**, 15, 270-9	5.1	47
124	ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity. *Molecular Cancer Research*, **2013**, 11, 736-47	6.6	25
123	Endocrine fibroblast growth factor FGF19 promotes prostate cancer progression. *Cancer Research*, **2013**, 73, 2551-62	10.1	62

122	Semaphorin 4F as a critical regulator of neuroepithelial interactions and a biomarker of aggressive prostate cancer. *Clinical Cancer Research*, **2013**, 19, 6101-11	12.9	29
121	The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer. *Cancer Research*, **2013**, 73, 3997-4008	10.1	29
120	SULT2B1b sulfotransferase: induction by vitamin D receptor and reduced expression in prostate cancer. *Molecular Endocrinology*, **2013**, 27, 925-39		32
119	FGFR1 is essential for prostate cancer progression and metastasis. *Cancer Research*, **2013**, 73, 3716-24	10.1	70
118	Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. *Cancer Research*, **2013**, 73, 2718-36	10.1	174
117	ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC). *PLoS ONE*, **2013**, 8, e72829	3.7	18
116	Notch and TGF form a reciprocal positive regulatory loop that suppresses murine prostate basal stem/progenitor cell activity. *Cell Stem Cell*, **2012**, 11, 676-88	18	63
115	Frequent heterogeneous missense mutations of GGAP2 in prostate cancer: implications for tumor biology, clonality and mutation analysis. *PLoS ONE*, **2012**, 7, e32708	3.7	5
114	Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. *Cancer Cell*, **2012**, 21, 253-65	24.3	252
113	Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. *Cancer Research*, **2012**, 72, 616-25	10.1	97
112	Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression. *Clinical Cancer Research*, **2012**, 18, 3880-8	12.9	39
111	Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. *Clinical Cancer Research*, **2012**, 18, 6648-57	12.9	46
110	Activation of Wnt signaling by chemically induced dimerization of LRP5 disrupts cellular homeostasis. *PLoS ONE*, **2012**, 7, e30814	3.7	14
109	Determining prostate cancer-specific death through quantification of stromogenic carcinoma area in prostatectomy specimens. *American Journal of Pathology*, **2011**, 178, 79-87	5.8	46
108	Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. *PLoS ONE*, **2011**, 6, e21319	3.7	18
107	Associations between arachidonic acid metabolism gene polymorphisms and prostate cancer risk. *Prostate*, **2011**, 71, 1382-9	4.2	17
106	Recurrent chimeric RNAs enriched in human prostate cancer identified by deep sequencing. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 9172-7	11.5	134
105	Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. *Cancer Research*, **2011**, 71, 572-82	10.1	114

104	GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction. *Cancer Research*, **2011**, 71, 7694-704	10.1	24
103	GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. *Clinical Cancer Research*, **2011**, 17, 7174-82	12.9	28
102	Activation of NF-{kappa}B by TMPRSS2/ERG Fusion Isoforms through Toll-Like Receptor-4. *Cancer Research*, **2011**, 71, 1325-33	10.1	62
101	FGFR-4 Arg□enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling. *Clinical Cancer Research*, **2011**, 17, 4355-66	12.9	37
100	Transcriptional and post-transcriptional regulation of Sprouty1, a receptor tyrosine kinase inhibitor in prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2011**, 14, 279-85	6.2	18
99	INPP4B: the new kid on the PI3K block. *Oncotarget*, **2011**, 2, 321-8	3.3	84
98	SENP1 induces prostatic intraepithelial neoplasia through multiple mechanisms. *Journal of Biological Chemistry*, **2010**, 285, 25859-66	5.4	82
97	Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. *Endocrine-Related Cancer*, **2010**, 17, 1021-33	5.7	49
96	Identification of differentially methylated genes in normal prostate tissues from African American and Caucasian men. *Clinical Cancer Research*, **2010**, 16, 3539-47	12.9	97
95	The function of microRNAs, small but potent molecules, in human prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2010**, 13, 208-17	6.2	41
94	Dicer ablation impairs prostate stem cell activity and causes prostate atrophy. *Stem Cells*, **2010**, 28, 1260-9	5.8	18
93	TGF-□1 induces an age-dependent inflammation of nerve ganglia and fibroplasia in the prostate gland stroma of a novel transgenic mouse. *PLoS ONE*, **2010**, 5, e13751	3.7	28
92	GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression. *Cancer Research*, **2009**, 69, 819-27	10.1	33
91	Global gene expression analysis of reactive stroma in prostate cancer. *Clinical Cancer Research*, **2009**, 15, 3979-89	12.9	123
90	DNA methylation and aberrant expression of Sprouty1 in human prostate cancer. *Epigenetics*, **2009**, 4, 54-61	5.7	17
89	Paths of FGFR-driven tumorigenesis. *Cell Cycle*, **2009**, 8, 580-8	4.7	115
88	Relaxin/RXFP1 signaling in prostate cancer progression. *Annals of the New York Academy of Sciences*, **2009**, 1160, 379-80	6.5	17
87	Variable frequency of polyomavirus SV40 and herpesvirus EBV in lymphomas from two different urban population groups in Houston, TX. *Journal of Clinical Virology*, **2009**, 46, 154-60	14.5	11

86	Genomic profiling of prostate cancers from African American men. *Neoplasia*, **2009**, 11, 305-12	6.4	32
85	Widespread deregulation of microRNA expression in human prostate cancer. *Oncogene*, **2008**, 27, 1788-93	7.2	545
84	Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression. *Neoplasia*, **2008**, 10, 847-56	6.4	76
83	Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. *Cancer Research*, **2008**, 68, 8516-24	10.1	139
82	Bortezomib-mediated inhibition of steroid receptor coactivator-3 degradation leads to activated Akt. *Clinical Cancer Research*, **2008**, 14, 7511-8	12.9	25
81	Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. *Cancer Research*, **2008**, 68, 5460-8	10.1	89
80	Cancer-related axonogenesis and neurogenesis in prostate cancer. *Clinical Cancer Research*, **2008**, 14, 7593-603	12.9	176
79	Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. *International Journal of Cancer*, **2008**, 123, 543-51	7.5	62
78	Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling. *PLoS ONE*, **2008**, 3, e2079	3.7	97
77	Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition. *Cancer Cell*, **2007**, 12, 559-71	24.3	232
76	Relaxin promotes prostate cancer progression. *Clinical Cancer Research*, **2007**, 13, 1695-702	12.9	80
75	Oxygen tension directs chondrogenic differentiation of myelo-monocytic progenitors during endochondral bone formation. *Tissue Engineering*, **2007**, 13, 2011-9		12
74	Age-related DNA methylation changes in normal human prostate tissues. *Clinical Cancer Research*, **2007**, 13, 3796-802	12.9	182
73	Enhanced survival in perineural invasion of pancreatic cancer: an in vitro approach. *Human Pathology*, **2007**, 38, 299-307	3.7	78
72	Hypoxic adipocytes pattern early heterotopic bone formation. *American Journal of Pathology*, **2007**, 170, 620-32	5.8	115
71	PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. *International Journal of Cancer*, **2006**, 118, 1471-80	7.5	47
70	Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. *Cancer Research*, **2006**, 66, 11039-46	10.1	98
69	Stromal antiapoptotic paracrine loop in perineural invasion of prostatic carcinoma. *Cancer Research*, **2006**, 66, 5159-64	10.1	69

68	Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. *Cancer Research*, **2006**, 66, 1880; author reply 1880-1	10.1	53
67	Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. *Cancer Research*, **2006**, 66, 10594-602	10.1	144
66	CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. *Cancer Biology and Therapy*, **2006**, 5, 78-83	4.6	23
65	Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. *Cancer Research*, **2006**, 66, 8347-51	10.1	326
64	Gene expression profiling and analysis of signaling pathways involved in priming and differentiation of human neural stem cells. *Neuroscience*, **2006**, 138, 133-48	3.9	20
63	A working group classification of focal prostate atrophy lesions. *American Journal of Surgical Pathology*, **2006**, 30, 1281-91	6.7	97
62	Bystin in perineural invasion of prostate cancer. *Prostate*, **2006**, 66, 266-72	4.2	31
61	Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. *Prostate*, **2006**, 66, 613-24	4.2	68
60	Comparison of the growth-promoting effects of testosterone and 7-alpha-methyl-19-nor-testosterone (MENT) on the prostate and levator ani muscle of LPB-tag transgenic mice. *Prostate*, **2006**, 66, 369-76	4.2	12
59	The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase. *Prostate*, **2006**, 66, 847-57	4.2	43
58	Increased expression of the metastasis-associated gene Ehm2 in prostate cancer. *Prostate*, **2006**, 66, 1641-52	4.2	23
57	PSGR2, a novel G-protein coupled receptor, is overexpressed in human prostate cancer. *FASEB Journal*, **2006**, 20, A936	0.9	
56	Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. *Cancer Research*, **2005**, 65, 7959-67	10.1	171
55	SRC-3 is required for prostate cancer cell proliferation and survival. *Cancer Research*, **2005**, 65, 7976-83	10.1	193
54	Increased expression of prostate-specific G-protein-coupled receptor in human prostate intraepithelial neoplasia and prostate cancers. *International Journal of Cancer*, **2005**, 113, 811-8	7.5	47
53	Mutation of the androgen receptor causes oncogenic transformation of the prostate. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 1151-6	11.5	154
52	Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer. *Clinical Cancer Research*, **2005**, 11, 4701-6	12.9	56
51	Artificial Neural Network Analysis of DNA Microarray-based Prostate Cancer Recurrence **2005**,		8

50	Duffy Antigen/Receptor for Chemokines (DARC): Is There a Role in Prostate Cancer?.. *Blood*, **2005**, 106, 4394-4394	2.2	
49	RTVP-1, a tumor suppressor inactivated by methylation in prostate cancer. *Cancer Research*, **2004**, 64, 969-76	10.1	57
48	The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression. *Clinical Cancer Research*, **2004**, 10, 6169-78	12.9	127
47	The expression of Sprouty1, an inhibitor of fibroblast growth factor signal transduction, is decreased in human prostate cancer. *Cancer Research*, **2004**, 64, 4728-35	10.1	106
46	Mismatch repair gene expression and genetic instability in testicular germ cell tumor. *Cancer Biology and Therapy*, **2004**, 3, 977-82	4.6	47
45	Chronic activity of ectopic type 1 fibroblast growth factor receptor tyrosine kinase in prostate epithelium results in hyperplasia accompanied by intraepithelial neoplasia. *Prostate*, **2004**, 58, 1-12	4.2	36
44	FGF17 is an autocrine prostatic epithelial growth factor and is upregulated in benign prostatic hyperplasia. *Prostate*, **2004**, 60, 18-24	4.2	21
43	Interleukin-8 expression is increased in senescent prostatic epithelial cells and promotes the development of benign prostatic hyperplasia. *Prostate*, **2004**, 60, 153-9	4.2	87
42	The role of fibroblast growth factors and their receptors in prostate cancer. *Endocrine-Related Cancer*, **2004**, 11, 709-24	5.7	267
41	Growth and survival mechanisms associated with perineural invasion in prostate cancer. *Cancer Research*, **2004**, 64, 6082-90	10.1	173
40	Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. *Cancer Research*, **2004**, 64, 2270-305	10.1	489
39	Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor. *Melanoma Research*, **2004**, 14, 13-21	3.3	25
38	Cellular senescence in the pathogenesis of benign prostatic hyperplasia. *Prostate*, **2003**, 55, 30-8	4.2	120
37	Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. *Prostate*, **2003**, 55, 219-37	4.2	358
36	Glutathione S-transferase pi is upregulated in the stromal compartment of hormone independent prostate cancer. *Prostate*, **2003**, 56, 98-105	4.2	7
35	In vivo preservation of steroid specificity in CWR22 xenografts having a mutated androgen receptor. *Prostate*, **2003**, 57, 1-7	4.2	9
34	Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. *Cancer Research*, **2003**, 63, 5754-60	10.1	91
33	Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation. *Cancer Research*, **2003**, 63, 6237-43	10.1	57

32	Inducible prostate intraepithelial neoplasia with reversible hyperplasia in conditional FGFR1-expressing mice. *Cancer Research*, **2003**, 63, 8256-63	10.1	55
31	Cooperation between ectopic FGFR1 and depression of FGFR2 in induction of prostatic intraepithelial neoplasia in the mouse prostate. *Cancer Research*, **2003**, 63, 8784-90	10.1	37
30	Impact of preimmunization on adenoviral vector expression and toxicity in a subcutaneous mouse cancer model. *Molecular Therapy*, **2002**, 6, 342-8	11.7	52
29	Alternative splicing of fibroblast growth factor receptors in human prostate cancer. *Prostate*, **2001**, 46, 163-72	4.2	74
28	Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 11563-8	11.5	260
27	Role of fibroblast growth factor receptor signaling in prostate cancer cell survival. *Journal of the National Cancer Institute*, **2001**, 93, 1783-90	9.7	67
26	Interleukin-8 is a paracrine inducer of fibroblast growth factor 2, a stromal and epithelial growth factor in benign prostatic hyperplasia. *American Journal of Pathology*, **2001**, 159, 139-47	5.8	101
25	Interleukin-6 is an autocrine growth factor in human prostate cancer. *American Journal of Pathology* , **2001**, 159, 2159-65	5.8	263
24	Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. *Cancer Research*, **2001**, 61, 3882-5	10.1	154
23	FGF-10 is expressed at low levels in the human prostate. *Prostate*, **2000**, 44, 334-8	4.2	17
22	Interleukin-1alpha is a paracrine inducer of FGF7, a key epithelial growth factor in benign prostatic hyperplasia. *American Journal of Pathology*, **2000**, 157, 249-55	5.8	61
21	Androgen receptor mutations in prostate cancer. *Cancer Research*, **2000**, 60, 944-9	10.1	224
20	Increased expression of fibroblast growth factor 6 in human prostatic intraepithelial neoplasia and prostate cancer. *Cancer Research*, **2000**, 60, 4245-50	10.1	60
19	Elevated caveolin-1 levels in African-American versus white-American prostate cancer. *Clinical Cancer Research*, **2000**, 6, 3430-3	12.9	38
18	Mitogenic activation of human prostate-derived fibromuscular stromal cells by bradykinin. *British Journal of Pharmacology*, **1999**, 127, 220-6	8.6	12
17	FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. *Journal of Cellular Physiology*, **1999**, 180, 53-60	7	58
16	Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. *Prostate*, **1999**, 40, 172-7	4.2	59
15	Alterations in expression of basic fibroblast growth factor (FGF) 2 and its receptor FGFR-1 in human prostate cancer. *Clinical Cancer Research*, **1999**, 5, 1063-71	12.9	197

14	Endothelin-1 production and agonist activities in cultured prostate-derived cells: implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. *Prostate*, **1998**, 34, 241-50	4.2	38
13	Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. *Proceedings of the National Academy of Sciences of the United States of America*, **1998**, 95, 5672-7	11.5	493
12	PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science*, **1997**, 275, 1943-7	33.3	4006
11	Transthyretin Ile 122 and cardiac amyloidosis in African-Americans. 2 case reports. *Texas Heart Institute Journal*, **1997**, 24, 45-52	0.8	17
10	Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma. *Prostate*, **1996**, 28, 275-81	4.2	25
9	Allelic loss on chromosome 10 in prostate adenocarcinoma. *Cancer Research*, **1996**, 56, 2143-7	10.1	74
8	The BN51 protein is a polymerase (Pol)-specific subunit of RNA Pol III which reveals a link between Pol III transcription and pre-rRNA processing. *Molecular and Cellular Biology*, **1995**, 15, 94-101	4.8	12
7	Alterations in the p53 and MDM-2 genes are infrequent in clinically localized, stage B prostate adenocarcinomas. *American Journal of Pathology*, **1994**, 145, 287-93	5.8	41
6	Protection of mice against tumor growth by immunization with an oncogene-encoded growth factor. *Proceedings of the National Academy of Sciences of the United States of America*, **1990**, 87, 4222-5	11.5	14
5	Chromosomal localization of human genes required for G1 progression in mammalian cells. *Genomics*, **1989**, 4, 240-5	4.3	12
4	Organization and expression of the cell cycle gene, ts11, that encodes asparagine synthetase. *Molecular and Cellular Biology*, **1989**, 9, 2350-2359	4.8	22
3	Molecular cloning of a gene that is necessary for G1 progression in mammalian cells. *Proceedings of the National Academy of Sciences of the United States of America*, **1987**, 84, 1565-9	11.5	47
2	An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family. *Cell*, **1987**, 50, 729-37	56.2	514
1	Isolation of the human gene that complements a temperature-sensitive cell cycle mutation in BHK cells. *Molecular and Cellular Biology*, **1987**, 7, 3386-3393	4.8	18